according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 03/06/2023 09/30/2023 595267-00020 Date of first issue: 04/04/2016 5.1

SECTION 1. IDENTIFICATION

Ertugliflozin (< 2%) / Sitagliptin Formulation Product name

No data available Other means of identification

Manufacturer or supplier's details

Company name of supplier Merck & Co., Inc Address 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone 908-740-4000 Emergency telephone 1-908-423-6000

E-mail address EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use **Pharmaceutical** Restrictions on use Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Skin irritation Category 2

Eye irritation Category 2A

Skin sensitization Category 1

Specific target organ toxicity - repeated exposure (Oral)

: Category 2 (Kidney, Stomach, Prostate)

GHS label elements

Hazard pictograms





Signal Word Warning

H315 Causes skin irritation. **Hazard Statements**

> H317 May cause an allergic skin reaction. H319 Causes serious eye irritation.

H373 May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

Precautionary Statements Prevention:

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P272 Contaminated work clothing should not be allowed out of

the workplace.

P280 Wear protective gloves, eye protection and face protec-

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

tion.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P314 Get medical attention if you feel unwell.

P333 + P313 If skin irritation or rash occurs: Get medical atten-

tion

P337 + P313 If eye irritation persists: Get medical attention. P362 + P364 Take off contaminated clothing and wash it before

reuse.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Sitagliptin		654671-77-9	>= 30 - < 60 *
Cellulose	No data availa- ble	9004-34-6	>= 30 - < 60 *
Ertugliflozin	No data availa- ble	1210344-83-4	>= 1 - < 5 *
Magnesium stearate	Octadecanoic acid, magnesi- um salt (2:1)	557-04-0	>= 1 - < 5 *
Propyl 3,4,5- trihydroxybenzoate	Benzoic acid, 3,4,5-trihydroxy- , propyl ester	121-79-9	>= 0.1 - < 1 *

^{*} Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention.

Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

and effects, both delayed

Causes skin irritation.

May cause an allergic skin reaction.

Causes serious eye irritation.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Oxides of phosphorus

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation Advice on safe handling

Do not get on skin or clothing.

Do not breathe dust. Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 03/06/2023

 5.1
 09/30/2023
 595267-00020
 Date of first issue: 04/04/2016

		exposure)	concentration	
Sitagliptin	654671-77-9	TWA	0.5 mg/m3 (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Ertugliflozin	1210344-83- 4	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm ²	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m ³	CA AB OEL
		TWAEV	10 mg/m³	CA QC OEL
		TWA (Inhal- able)	10 mg/m³	CA BC OEL
		TWA (Respirable)	3 mg/m³	CA BC OEL
		TWA (Inhalable particulate matter)	10 mg/m³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices).

Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

Sitagliptin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

LD50 (Mouse): 3,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Ertugliflozin:

Acute oral toxicity : LD50 (Rat): 500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Acute oral toxicity : LD50 (Mouse, female): > 1,000 - 2,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Causes skin irritation.

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

Components:

Sitagliptin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Ertugliflozin:

Result : Corrosive

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Species : reconstructed human epidermis (RhE)

Method : OECD Test Guideline 439

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Sitagliptin:

Species : Rabbit

Result : Irritating to eyes. Method : Draize Test

Ertugliflozin:

Result : Severe irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Species : Rabbit

Result : Irreversible effects on the eye Method : OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

Respiratory sensitization

Not classified based on available information.

Components:

Sitagliptin:

Test Type : Local lymph node assay (LLNA)

Species : Mouse

Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

Ertugliflozin:

Test Type : Local lymph node assay (LLNA)

Result : Not a skin sensitizer.

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact
Species : Mouse
Result : positive

Assessment : Probability or evidence of skin sensitization in humans

Germ cell mutagenicity

Not classified based on available information.

Components:

Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

Application Route: Oral

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Ertugliflozin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: positive

Test Type: Chromosome aberration test in vitro

Result: positive

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Test Type: In vitro sister chromatid exchange assay in mam-

malian cells Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Sitagliptin:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat

Application Route : oral (drinking water)

Exposure time : 2 Years
Result : positive
Target Organs : Liver

Remarks : Significant toxicity observed in testing

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Ertugliflozin:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Propyl 3,4,5-trihydroxybenzoate:

Species : Rat
Application Route : Ingestion
Exposure time : 103 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Parent: 1,000 mg/kg body weight Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit

Teratogenicity: NOAEL: 125 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Ertugliflozin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL: 250 mg/kg body weight Remarks: Maternal toxicity observed.

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

No significant adverse effects were reported

Test Type: Fertility/early embryonic development

Species: Rabbit Application Route: Oral

Fertility: NOAEL: 200 mg/kg body weight

Remarks: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 50 mg/kg body weight Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 250 mg/kg body weight Remarks: No significant adverse effects were reported

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

Components:

Ertugliflozin:

Routes of exposure : Oral

Target Organs : Kidney, Stomach, Prostate

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Sitagliptin:

Species : Mouse
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg

Application Route : Oral
Exposure time : > 2 y
Target Organs : Kidney

Species : Rat

NOAEL : 500 mg/kg LOAEL : 1,000 mg/kg

Application Route : Oral Exposure time : 14 Weeks

Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 27 Weeks

Target Organs : Skeletal muscle, Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Ertugliflozin:

Species : Rat

LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species : Rat
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d

Target Organs : Kidney, Bone, Stomach

Species : Rat LOAEL : 25 mg/kg Exposure time : 90 d

Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 270 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone

Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg Application Route : Ingestion

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

Exposure time : 90 Days

Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Species : Rat
NOAEL : 135 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Sitagliptin:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis,

Headache

Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis,

Headache, Nausea, Abdominal pain, Diarrhea

Ertugliflozin:

Ingestion : Symptoms: The most common side effects are:, Headache,

constipation, Diarrhea, Nausea, urinary tract infection, muscle

pain, upper respiratory tract infection

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Sitagliptin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 60 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 39

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox- : NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

icity) Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chron-

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 9.8 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 150 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Ertugliflozin:

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 1 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 2.14 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Magnesium stearate:

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 19.06 mg/l

Exposure time: 48 h

Test substance: Neutralized product Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): 0.37

mg/l

Exposure time: 72 h

Test substance: Neutralized product Method: OECD Test Guideline 201

EC10 (Pseudokirchneriella subcapitata (green algae)): 0.17

mg/l

Exposure time: 72 h

Test substance: Neutralized product Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: 636 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 595267-00020 Date of first issue: 04/04/2016

Persistence and degradability

Components:

Sitagliptin:

Biodegradability : Result: not rapidly degradable

Biodegradation: 39.7 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)

Method: OECD Test Guideline 111

Cellulose:

Biodegradability : Result: Readily biodegradable.

Ertugliflozin:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 40.8 % Exposure time: 28 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 49.4 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Bioaccumulative potential

Components:

Sitagliptin:

Partition coefficient: n-

log Pow: -0.03

octanol/water Ertugliflozin:

Partition coefficient: n-

: log Pow: 2.47

octanol/water

Magnesium stearate:

Partition coefficient: n-

log Pow: > 4

octanol/water

Propyl 3,4,5-trihydroxybenzoate:

Partition coefficient: n- : log Pow: 1.8

octanol/water Remarks: Calculation

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: 5.1 09/30/2023

SDS Number: 595267-00020

Date of last issue: 03/06/2023 Date of first issue: 04/04/2016

Mobility in soil

Components:

Sitagliptin:

Distribution among environmental compartments

log Koc: 4.37

Ertugliflozin:

Distribution among environmental compartments

: log Koc: 2.88

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average CA AB OEL / TWA : 8-hour Occupational exposure limit CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level: NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

according to the Hazardous Products Regulations



Ertugliflozin (< 2%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 595267-00020 Date of first issue: 04/04/2016

compile the Material Safety

eChem Portal search results and European Chemicals Agen-

Data Sheet

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8